GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

NorthSea Therapeutics B.V. (?NST', or the ?Company'), a private, late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, today ...

GSK and other pharma companies that have sold ranitidine products over the years have so far been fairly successful in fending off the litigation, with wins in the US and Canada, and the Delaware ...

An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...

The mouse on the right with four times the normal muscle mass is placed with a normal mouse. Handout via REUTERS About a dozen drugmakers are developing new weight-loss treatments aimed at ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...

The Public Health Agency of Canada says the purchase of 500,000 vaccines are a 'proactive' measure to ensure the doses are ready if they need to be used.

2025 Drug distributor Cardinal Health said on Thursday it may need to increase prices of some of its products if the proposed tariffs on Mexico go into effect, to counter increasing costs of ...

What considerations should developers in Denver-Boulder keep in mind when planning future life sciences facilities, particularly around the flexibility required for evolving technologies?